BETR BetterLife Pharma Inc.
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.…
Industry Peers
BiotechnologyKey Statistics
About BetterLife Pharma (CNSX: BETR)
›
BetterLife Pharma (CNSX: BETR) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.1900 CAD on 19 November 2026, up 171.4% over 52 weeks. Its 52-week range is 0.0400 CAD to 0.3550 CAD: the price is 46.5% below the high and 375.0% above the low.
Its market capitalisation is 123.75M CAD.
BetterLife Pharma reports return on equity of 15.3% and an operating margin of 0.0%.
Its debt exceeds its cash by 1.92M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.